Abortion Pill Maker Seeks Mail-Order Access

A legal battle over abortion access moved back to the nation’s highest court on Saturday, as the maker of mifepristone asked the US supreme court to stop a ruling that would force patients to get an in-person exam before receiving the drug.

Danco Laboratories filed an emergency appeal after the fifth US circuit court of appeals temporarily restored that requirement, according to reports. The lower court action blocks telemedicine providers from prescribing the medication by mail in response to a challenge from Louisiana, tightening access to one of the most closely watched drugs in the country’s abortion debate.

The immediate fight centers on a simple but consequential question: can patients receive mifepristone through telemedicine and mail-order prescribing, or must they appear in person first?

The dispute reaches beyond one company and one pill. Mifepristone sits at the center of medication abortion in the US, and rules around how doctors prescribe it have become a major front in the wider struggle over reproductive healthcare. When courts change those rules, providers must scramble and patients can face sudden new barriers, especially in places where clinic access already runs thin.

The emergency filing also shows how quickly abortion policy can shift through the courts. A single appellate move can alter care nationwide or in large regions, even before judges fully resolve the underlying case. That leaves providers, patients, and state officials navigating a patchwork of changing rules while the legal fight continues.

What happens next matters well beyond this appeal. If the supreme court intervenes, it could preserve mail-order access to mifepristone for now; if it does not, the in-person requirement could reshape how patients obtain the medication in the near term. Either way, the case signals that access to abortion pills remains a live and volatile battleground in the US legal system.